<DOC>
	<DOC>NCT00234936</DOC>
	<brief_summary>The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.</brief_summary>
	<brief_title>Quality of Life Study With Adalimumab in Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history Subject has a diagnosis of rheumatoid arthritis as defined by the 1987 ACR criteria Subjects with treatment failure criteria to Mtx or Mtx + another DMARD Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study Female subject who is pregnant or breastfeeding or considering becoming pregnant Previous treatment with approved biological agents (etanercept, infliximab, anakinra) in the last 2 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>adalimumab</keyword>
	<keyword>quality of life</keyword>
</DOC>